anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this Phase II research project is to evaluate and market an innovative health message intervention to increase uptake of the human papillomavirus (HPV) vaccine and reduce women's cervical cancer risk through partnership with Planned Parenthood. The overall aim is to reach a broad population through Planned Parenthood, the nation's leading sexual and reproductive health care center, especially among low socioeconomic status (SES) and historically underserved populations. Despite an overall increase in vaccination and reduction in HPV-related infections in younger populations targeted by previous health promotion efforts, young adult women who are recommended for vaccination demonstrate much lower vaccination rates and higher rates of infection. In a recent Phase I grant, the investigators developed and demonstrated the usability and feasibility of an innovative, culturally-grounded, technology-based narrative intervention that delivers decision narratives in the form of videos via a health kiosk, an underutilized communication strategy for reaching less involved audiences. This brief, low-cost, easily implementable intervention doubled the uptake of the vaccine in a separate pilot study. The proposed Phase II project will: (1) Complete development of the intervention, (2) Evaluate its effectiveness through a randomized clinical trial, and (3) Prepare the product for the market. To accomplish these aims, the investigators will develop the intervention for implementation in waiting rooms as part of check-in procedures. Development includes programming and installing tablets to accomplish these tasks (Aim 1). The investigators will then conduct the evaluation study in four Planned Parenthood clinics in southeastern Pennsylvania (Aim 2). Eligible women will be consented, complete a pretest, and then randomized to view the brief intervention or attention control messages via the tablet. After viewing the messages, the participants will complete a short posttest. Treatment participants will receive follow up texts/emails as reminders to vaccinate, and all participants will receive texts/emails with links that allow completion of posttest surveys at 3- and 9 months. Finally, the investigators will prepare the intervention for the market that includes not only Planned Parenthood but other clinics that are currently served by the project partners as well as the broader market for HPV vaccination (Aim 3). In summary, the proposed communication strategy has wide reaching implications not only for reducing cancer risk, but more broadly for designing brief and easily implemented prevention messages across many domains of public health. The research will also close the health disparities gap in minority, under-served young adult women's access to preventive health care.
FIELD: medicine, phytotherapy. SUBSTANCE: invention relates to the development of medicinal agent of vegetable origin and method of treatment of locomotor system diseases by phytosteaming therapy method. Species comprises 45 plants taken in the equal ratio. Invention proposes method of treatment of locomotor system diseases including phytosteaming therapy using the proposed species, intake of phytotea with this species and rubbing in a mixture of evaporated concentrate of the same species with 96% alcohol in spine and joints region. Method provides clearance of body at tissue and cellular level by effect on human body using curative steaming concentrate and phytobarrel. This agent can be used in prophylaxis and curative aim for treatment of locomotor system diseases. The proposed agent and method of treatment ensure to use the proposed procedure for treatment of different sicknesses of locomotor system, among them so called "incurable" ones, for example, rheumatic polyarthritis and Bekhterev's disease. EFFECT: improved method of treatment. 3 cl, 2 ex
There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference for one method over another since comparative evidence from larger data sets is lacking. To improve the evidence base, we analyzed the outcome of rATG vs. PTCy prophylaxis in adult patients with hematologic malignancies undergoing first peripheral blood alloSCT from MMUD (9/10 antigen match) between Jan 2018 and June 2021 in the database of the European Society for Blood and Marrow Transplantation (EBMT). We performed multivariate analyses using the Cox proportional-hazards regression model. We included 2123 patients in the final analyses (PTCy, n = 583; rATG, n = 1540). p values and hazard ratios (HR) presented here are multivariate outcomes. Two years after alloSCT we found a lower NRM in the PTCy group of 18% vs. 24.9% in the rATG group; p = 0.028, HR 0.74. Overall survival in the PTCy cohort was higher with 65.7% vs. 55.7% in the rATG cohort; p < 0.001, HR 0.77. Progression-free survival was also better in the PTCy patients with 59.1% vs. 48.8% when using rATG; p = 0.001, 0.78. The incidences of chronic GVHD and acute GVHD were not significantly different between the groups. We found significantly lower NRM as well as higher survival in recipients of peripheral blood alloSCTs from MMUD receiving PTCy as compared to rATG. The results of the current analysis suggest an added value of PTCy as GVHD prophylaxis in MMUD alloSCT.
A polypeptide may include an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 42, wherein a residue at position 94 of the polypeptide is an amino acid other than threonine or wherein a residue at position 82 of the polypeptide is an amino acid other than serine. A polypeptide may include at least the first 14 residues and at most the first 92 residues of an amino acid sequence starting with residue 1 of, and having at least about 95% identity to, the amino acid sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 16, or 17. Such polypeptide may stimulate neurite outgrowth or neurogenesis. A nucleic acid may encode the polypeptide. A vector may include the nucleic acid. A host cell, such as an embryonic stem cell, may include the vector.
BACKGROUND: There is an urgent need to identify a robust predictor for BCG response in patients with non-muscle-invasive bladder cancer (NMIBC). We aimed to employ the Lasso regression model for the selection and construction of an index (BCGI) utilizing inflammation and nutrition indicators to predict the response to BCG therapy.
METHODS: After acquiring the ethics approval, we searched the electric medical records in our institution and performed data screening. Then, we developed the BCGI using a Lasso regression model and subsequently evaluated its performance in both the train and internal test datasets through Kaplan-Meier survival curves and Cox regression analysis. Then, we also evaluated the prognostic value of BCGI alongside the EAU2021 model.
RESULTS: The training dataset and internal test dataset contained 295 and 196 patients, respectively. Referring to the Lasso results, BCGI consisted of hemoglobin, albumin, and platelet count, which could significantly predict the recurrence of NMIBC patients who accepted BCG in train (P = .012) and test (P = .004) datasets. The BCGI also exhibited statistically prognostic value in no smoking history, World Health Organization high grade, and T1 subgroups, both in train and test datasets. In multivariable analysis, BCGI exhibited independent prognostic value in train (P = .012) and test (P = .012) datasets. Finally, we constructed a nomogram that consisted of smoking history, T stage, World Health Organization grade, tumor size, and BCGI. Then, BCGI demonstrated significant independent prognostic value in NMIBC patients treated with BCG, a result not observed with the EAU2021 score or classification.
CONCLUSION: Based on the results, we reasonably suggest that BCGI may be a useful predictor for NMIBC patients who accepted BCG. Furthermore, we have demonstrated the efficacy of constructing a prognostic index using clinical factors and a Lasso regression model, a versatile approach applicable to various medical conditions.
Patients with KRAS WT advanced solid tumor malignancies with MET-amplification were to receive Sym015 at the RP2D. Included in this group was a subset of patients who have received prior therapy with a MET-targeting TKI.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to cosmetology and physiotherapy. Procedure is performed by the CarboxyPen apparatus by mesotherapeutic introduction of carbon dioxide, by means of mesotherapeutic needles, 30G by the Gauge scale, with length from 6 to 13 mm: intracutaneously or subcutaneously, in 3–10 points, at depth of 3–6 mm. At that, 2 to 5 ml of carbon dioxide is used for 1 prick-in. Total amount of carbon dioxide per one procedure makes 10–20 ml. Therapeutic course makes 5-6 times, every other day. Carbon dioxide injections are carried out near skin areas where there are manifestations of edema and neuropathies at distance of 0.1–1 cm from them and along the postaural, submandibular and neck reservoirs at distance of 0.1–1 cm.EFFECT: method enables higher accuracy, preventive action, reduced length of treatment, reduced costs and simplified technology of medical rehabilitation and therapy in cosmetology.1 cl, 2 ex
Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
Two administrations of 5 million autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 (TolDCB29). This cohort will consist of three patients.
Heart failure causes limitation of functional capacity and worsening of exercise tolerance. The airway pressure as adjuvant of cardiac rehabilitation has demonstrated improvement of functional capacity, decrease of respiratory work, increase of oxygenation and pulmonary compliance. Objective: to evaluate the effectiveness of the bilevel positive airway pressure (BILEVEL) in the increase of exercise tolerance in patients with decompensated heart failure. Method: this is a cross-over randomized clinical trial, with individuals who will undergo a submaximal progressive exercise test of the lower limbs with a cycle-ergometer using continuous positive airway pressure (CPAP) and BILEVEL in a random order. Patients will also be evaluated using a health related quality of life questionnaire, pulmonary function test, inspiratory muscle and peripheral muscle strength tests. Hypothesis: The increase in exercise tolerance might be greater during the use of BILEVEL.
BACKGROUND: Gastrointestinal dysfunction is a common complication of medical nutrition therapy in critically ill patients. Whether prone positioning leads to a deterioration in gastrointestinal function has not been fully clarified. Thus, we aimed to analyze the influence of prone positioning on the tolerance of medical nutrition therapy.
METHODS: We conducted a retrospective analysis of 102 SARS-CoV-2 infected patients with venovenous extracorporeal membrane oxygenation support (VV ECMO). Gastric residual volume (GRV) was used to assess the tolerance of enteral nutrition.
RESULTS: Nutritional data were collected for 2344 days. Undernutrition was observed in 40.8%, with a significantly higher incidence on days in prone position (48.4% versus 38.6%, p < 0.001). On days in supine position, significantly more calories were administered enterally than on days in prone position (p < 0.001). The mean GRV/24 h was 111.1 mL on days in supine position and 187.3 mL on days in prone position (p < 0.001). Prone positioning was associated with higher rates of GRV of ≥500 mL/24 h independent of age, disease severity at ECMO start, ECMO runtime and ICU length of stay (adjusted hazard ratio: 4.06; 95%CI: 3.0-5.5; p < 0.001).
CONCLUSIONS: Prone position was associated with lower tolerance of enteral nutrition, as indicated by an increased GRV. As a result, reduced enteral nutritional support was administered.
The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
Dysfunction of the vascular angiocrine system is critically involved in regenerative defects and fibrosis of injured organs. Previous studies have identified various angiocrine factors and found that risk factors such as aging and metabolic disorders can disturb the vascular angiocrine system in fibrotic organs. One existing key gap is what sense the fibrotic risk to modulate the vascular angiocrine system in organ fibrosis. Here, using human and mouse data, we discovered that the metabolic pathway hydrogen sulfide (H2S)-AMP-activated protein kinase (AMPK) is a sensor of fibrotic stress and serves as a key mechanism upregulating the angiocrine factor plasminogen activator inhibitor-1 (PAI-1) in endothelial cells to participate in lung fibrosis. Activation of the metabolic sensor AMPK was inhibited in endothelial cells of fibrotic lungs, and AMPK inactivation was correlated with enriched fibrotic signature and reduced lung functions in humans. The inactivation of endothelial AMPK accelerated lung fibrosis in mice, while the activation of endothelial AMPK with metformin alleviated lung fibrosis. In fibrotic lungs, endothelial AMPK inactivation led to YAP activation and overexpression of the angiocrine factor PAI-1, which was positively correlated with the fibrotic signature in human fibrotic lungs and inhibition of PAI-1 with Tiplaxtinin mitigated lung fibrosis. Further study identified that the deficiency of the antioxidative gas metabolite H2S accounted for the inactivation of AMPK and activation of YAP-PAI-1 signaling in endothelial cells of fibrotic lungs. H2S deficiency was involved in human lung fibrosis and H2S supplement reversed mouse lung fibrosis in an endothelial AMPK-dependent manner. These findings provide new insight into the mechanism underlying the deregulation of the vascular angiocrine system in fibrotic organs.
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to ophthalmology. In order to conduct ultraviolet cross-linking in progressive keratoconus in patients with initial corneal thickness on cone top of ≤ 400 mcm after de-epithelialization, patient's corneal thickness is measured. As a corneal protector solution, dextralink is used, after which the pachymetry of the cornea is re-determined in the thinnest place, and the thickness of the protective corneal protective flap is calculated in an original way. Protective flap is produced from the pre-stromal layer of a preserved donor cornea resected with the required thickness of 9.4 mm diameter, which is laid on the surface of the patient's cornea and aligned. After obtaining the necessary total thickness "patient cornea - a cornea flap stroma donor" ultraviolet irradiation is carried out procedure for patient through the protective corneal stroma of a donor cornea flap wavelength 370 nm capacity of 9 mW/cmfor 10 minutes with Dextralink parallel installations every 2 min. After irradiation, a protective flap of donor cornea stroma is removed.EFFECT: group of inventions provides a safe procedure for ultraviolet cross-linking by filling the patient's corneal thickness deficiency to the required value taking into account individual patient's thin corneal pachymetry values, absence of intra- and postoperative complications, improvement of strength properties of cornea, arrest of progression of keratoconus in remote postoperative period.2 cl, 2 ex
The invention discloses a compound Chinese herbal medicine preparation for promoting penaeus monodon smooth liver transforming and a use thereof. The compound Chinese herbal medicine preparation comprises radix bupleuri, fruit of Chinese magnoliavine, radix scutellariae, rheum officinale, oriental wormwood, licorice root and selenium malt powder. The above ingredients (without selenium malt powder) are mixed according to a certain ratio, the mixture is crushed by an ultrafine grinder, the powder is sieved by a sieve of 80 meshes, the sieved powder and selenium malt powder are uniformly mixed and then are packaged, and the packaged mixture is mixed with feed according to a ratio of 0.3-0.5% and then is used for oral administration. Monarch, minister, assistant and guide drugs of the compound Chinese herbal medicine preparation realize combination of prevention and treatment and produce synergism. Through combination of the modern nutrition theory and the traditional Chinese medicine health preserving and health care theory, penaeus monodon smooth liver transforming is promoted, penaeus monodon smooth liver diseases are prevented, diseases in a culture process are reduced and economic benefits are improved. The compound Chinese herbal medicine preparation has the advantages of reasonable and scientific formula, use convenience, no toxic and side effect and no drug residue.
The invention, which is called METRAFDIABETE, relates to novel pharmaceutical products, which are numbered 1, 2, 3 and 4 and which are obtained from extracts from the Anacardium occidentale, Moringa oleifera, Sclerocarya birrea and Prosopis africana medicinal plants, and the use thereof in the treatment of diabetic diseases.  Product number 1 corresponds to that obtained with extract from the bark of Anacardium occidentale.  Product number 2 corresponds to that obtained with extract from the leaves of Moringa oleifera.  Product number 3 corresponds to that obtained with extract from the roots of Sclerocarya birrea.  Product number 4 corresponds to that obtained with extract from the bark of Prosopis africana.  All the aforementioned products are obtained using the same production method and they are all in the form of conditioned powder, in gelatine capsules, capsules or sachets of granules having a unit weight of 2.08g.  One of said four medicaments is taken orally for 8-day increments until the clinical and paraclinical signs of the diabetes have completely disappeared.  The plant extracts used have a hypoglycemia action and, moreover, they facilitate the absorption of carbohydrates by the cells and tissues.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellent applicability and containing decreased amount of surfactant without deteriorating the characteristic functions of an emulsion composition such as cleaning action and penetrating action by using agar and/or gelatin in combination with a specific oily agent. SOLUTION: Agar and/or gelatin are used in combination with a volatile oily agent. The volatile oily agent preferably has a boiling point of <200 deg.C under atmospheric pressure and a viscosity of especially 0.1-10cSt and is one or more compounds selected from a dimethylpolysiloxane, a 3 to 6-mer of a cyclic dimethylpolysiloxane, a <20C branched hydrocarbon (e.g. isononane) and an ester having a total carbon number of <12 (e.g. ethyl isooctanate). Preferably, the content of the agar and/or gelatin is 0.1-5wt.% and that of the volatile oily agent is 1-90wt.% based on the total composition. The composition is useful as a cosmetic, especially cleansing cosmetic or pharmaceutical preparation for external use for skin.
The present invention is made for the purpose of improving beef quality a nd upgrading its fat marbling standard (which is called beef marbling standard, or BMS). The fat marbling state is generally called "Shimofuri" in Japanese. This purpose is achieved by vitamin C administration (L-ascorbic acid) to the cattle. The vitamin C can be administered by injection etc., but the easiest way is by oral administration. When only the vitamin C is administered orally, however, it is decomposed by microorganisms in the rume n and the desired effect cannot be obtained. For that reason, the vitamin C needs to b e coated with something so that it can be absorbed by the intestinal tract after passing through the stomach. Soybean-hydrogenated oil and fat is desirable for such covering material. An appropriate daily dose of the vitamin C is approximately 20 mg to b0 mg/kg of weight. According to the result of tests conducted on the Japanese Black Cattle, in terms of the yiel d, there is no significant difference between the cattle given the vitamin C and those not given it. In terms of the quality of the meat, however, there are significant differences in th e fat marbling (Shimofuri), luster, firmness and texture of the meat. >
Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle.
Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
Fluoroquinolones, including AVELOX, may cause central nervous system (CNS) events, including: nervousness, agitation, insomnia, anxiety, nightmares or paranoia [see Adverse Reactions (6.2, 6.4)].

Convulsions and increased intracranial pressure (including pseudotumor cerebri) have been reported in patients receiving fluoroquinolones. Fluoroquinolones may also cause central nervous system (CNS) events including: dizziness, confusion, tremors, hallucinations, depression, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving AVELOX , the drug should be discontinued and appropriate measures instituted. As with all fluoroquinolones, AVELOX should be used with caution in patients with known or suspected CNS disorders (for example, severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold [see Drug Interactions (7.4) Adverse Reactions (6.2, 6.4) and Patient Counseling Information (17.3)].
Prostate cancer (PCa) incidence and cancer-related deaths are both high in the male population. Once castration-resistant prostate cancer (CRPC) has developed, PCa can be difficult to manage. Circular RNAs (circRNAs) play essential roles in the regulation of carcinogenesis and cancer progression. In CRPC, however, the potential molecular mechanisms and biological functions of circRNAs are yet to be defined. In this study, we conducted RNA sequencing on four hormone-sensitive prostate cancer (HSPC) tumor tissue samples and three CRPC samples. We recognized hsa_circ_0001610, a novel circRNA that was highly expressed in the cells and tissue of CRPC. We used quantitative real-time PCR (qRT-PCR) to evaluate hsa_circ_0001610 expression. We conducted in vivo and in vitro experiments and found that hsa_circ_0001610 overexpression caused PCa cells to proliferate and migrate and caused enzalutamide resistance. In contrast, the opposite results were found for hsa_circ_0001610 knockdown. We used Western blot, dual-luciferase reporter assays, RNA immunoprecipitation (RIP), qRT-PCR, and rescue experiments to reveal the underlying mechanisms of hsa_circ_0001610. Mechanistically, hsa_circ_0001610 acted as a molecular sponge for miR-1324 and thus reversed its inhibitory effect on its target gene PTK6. As a result, the PTK6 expression was enhanced, which accelerated PCa progression. The findings of this study confirmed that hsa_circ_0001610 drives the progression of PCa through the hsa_circ_0001610/miR-1324/PTK6 axis. Thus, hsa_circ_0001610 is potentially an effective therapeutic target and specific biomarker for advanced PCa.